AOD-9604 human research: what the trials found and what they did not

TL;DR

• AOD-9604 is a modified peptide based on human growth hormone amino acids 177–191, but that chemical identity alone does not establish a human outcome.¹
• Small early human studies reported biological signals or modest numerical changes, yet their weight findings were not statistically different from placebo or lacked enough detail.²
• The larger 24-week OPTIONS trial found no statistically significant weight difference from placebo at its 12-week primary or 24-week secondary endpoint.³
• FDA later found the human safety record too limited for long-term conclusions and identified added concerns around some compounded formulations and routes.⁴

For Filipino readers, AOD-9604 presents a useful lesson in reading research as a sequence, not a slogan. The early story included animal findings, short human experiments, and one apparently encouraging study. The later story included a larger test that did not confirm a meaningful group difference. The fairest account keeps both parts visible while asking what each design could truly show.

First, separate the molecule from the message

AOD-9604 is a 16-amino-acid peptide built from the end region of human growth hormone, with an extra tyrosine added at the front.¹ Its name is often placed beside other “growth hormone fragment” labels, but a similar label does not prove that two materials are chemically identical or interchangeable.¹ The peptide’s origin also says nothing by itself about a result in people.¹

That distinction matters because the research began with a biological idea, then moved through several types of testing.⁵ A rat experiment reported less body-weight gain and more lipolytic activity in fat tissue after oral exposure.⁶ Those were animal findings, not human weight outcomes.⁶ Human trials still had to test whether a measurable difference appeared against placebo in defined groups.⁵ That is the key reading habit.

AOD-9604 is named here only to introduce the following neutral catalog reference.

The human program was a series, not one trial

FDA’s 2024 review traced six randomized, double-blind, placebo-controlled human studies from the development program.⁵ The studies used oral or intravenous routes, and most participants were adults with obesity.⁵ The sequence moved from single-exposure and short escalating-exposure work to two longer oral studies.⁵

This structure helps explain why one headline number cannot represent the whole program. Early studies often watched biomarkers, short-term weight change, and immediate safety measures.² Later studies tested group differences over 12 or 24 weeks.⁷ The largest study also included a supervised diet-and-exercise program for every group.⁸

There was another important limit: several results survived mainly as short summaries, meeting material, or company filings.⁵ FDA repeatedly noted missing methods, incomplete numerical detail, and no full medical-journal report for key studies.⁷ That leaves less room to inspect the analyses than a complete trial paper would provide.⁷

Early signals did not settle the weight question

One four-week study involved 23 men with obesity who received intravenous AOD-9604 or placebo.² Investigators reported a rise in non-esterified fatty acids, a marker tied to fat metabolism.² Average weight changed by 0.58 kilograms over three weeks, but the difference was not statistically significant versus placebo.²

A separate four-week study followed 16 men with obesity receiving three oral amounts or placebo.⁹ It also reported a rise in non-esterified fatty acids after exposure.⁹ Yet weight loss again did not differ significantly from placebo.⁹

A one-week study of 36 men produced another tempting number.¹⁰ Average change was 1.0 kilogram at one tested amount and 0.6 kilogram with placebo.¹⁰ Other amounts appeared less active, and the public summary gave no further details.¹⁰ Together, these studies show why a biomarker shift or small numerical gap should not be rewritten as a confirmed human outcome.²

The 300-person study looked encouraging but incomplete

The next study enrolled 300 adults with obesity after a two-week placebo run-in.⁷ Participants then received one of five daily oral AOD-9604 amounts or placebo for 12 weeks.⁷ A meeting abstract reported greater weight change across active groups, with the largest signal at 1 milligram.⁷

The pattern was not a simple rise in effect with higher amounts.⁷ Some group results were missing from the abstract, and a highlighted result applied to women at one amount.⁷ FDA described the differences as small and their practical meaning as unclear.⁷

Most importantly, FDA did not locate a full publication of the study’s methods and results.⁷ Readers therefore cannot examine the full analysis through a standard paper.⁷ The finding deserves mention because it was part of the program, but its thin reporting should travel with it in every summary.⁷

OPTIONS gave the idea a larger test

OPTIONS enrolled 536 adults with obesity and randomized 502 of them.⁸ Participants received one of three daily oral AOD-9604 amounts or placebo for 24 weeks.⁸ Every group also joined a dietitian-supervised diet-and-exercise program.⁸ The primary question was whether any tested amount produced a significant weight difference from placebo after 12 weeks.⁸

The answer was negative.³ None of the three active groups produced a statistically significant weight difference from placebo at 12 weeks.³ The 24-week secondary weight endpoint was also not statistically significant.³ The developer then ended the obesity program.³

This later result does not erase every observation from the smaller studies. It changes how those observations should be weighed. The larger test used a broader population, longer follow-up, and a direct placebo comparison under shared lifestyle conditions.⁸ Under those defined conditions, the earlier promise did not become a clear group-level weight result.³

For hGH fragment 176-191, the following card is a neutral catalog reference only.

Safety summaries need the same careful reading

The human studies tracked adverse events, laboratory measures, vital signs, ECG findings, glucose measures, and IGF-1 in selected settings.¹¹ Across oral studies, commonly reported events included headache, diarrhea, and flatulence.¹¹ The study authors reported no significant between-group differences in IGF-1 or routine laboratory, ECG, and vital-sign measures.¹¹

That summary sounds reassuring until its boundaries are restored. FDA noted incomplete event breakdowns, missing laboratory values, and exposure lasting no longer than 24 weeks.¹¹ Serious events also appeared in the program, including diarrhea, chest tightness, and several cancers.¹² FDA found too little detail to decide whether several serious events were related to AOD-9604.¹²

The trials therefore did not establish long-term safety.¹¹ The record describes what was reported during limited studies, along with major gaps in attribution and duration.¹² An event list cannot prove causation, while an incomplete list cannot rule risk out.¹²

Route and formulation gaps still matter

The reviewed human exposure came from oral and intravenous studies.¹³ FDA found the safety information insufficient for subcutaneous and transdermal assessment.¹³ It also found insufficient information for long-term use and route-specific immune-response assessment.¹³

These gaps matter because findings from one route should not be copied automatically to another.¹³ FDA says compounded AOD-9604 may pose immunogenicity concerns for certain routes.⁴ The agency also points to peptide impurities and active-ingredient characterization as possible issues.⁴ Those are formulation and manufacturing questions, not proof of a weight outcome.⁴

FDA’s overall evidence conclusion was also direct: the available record did not support effectiveness for obesity.⁴ That conclusion reflects the program as reviewed, especially the larger negative trial and the thin reporting around earlier work.⁴

Bottom line

AOD-9604 moved from animal research into several controlled human studies, so its history is more substantial than a single laboratory claim.⁵ Yet the direction of the human evidence matters. Small studies reported biomarkers, numerical changes, or an incomplete positive signal.² The larger OPTIONS trial did not find a significant weight difference from placebo at 12 or 24 weeks.³

Safety reporting was also bounded by short follow-up and incomplete detail.¹¹ FDA could not make firm causal judgments about several serious events and found important gaps for other routes.¹² The responsible reading is neither hype nor dismissal: it is a negative larger trial, limited safety evidence, and several questions the available human record cannot resolve.¹³

This article is educational research context, not medical advice. Catalog links are neutral references and do not imply a treatment or human-use recommendation.

Frequently asked questions

What exactly is AOD-9604?

AOD-9604 is a 16-amino-acid peptide based on human growth hormone residues 177–191, with an extra tyrosine at the front.¹ That definition identifies the research material. It does not establish a clinical effect, and it should not make readers assume that every similarly named growth hormone fragment is interchangeable.¹

Were there human trials?

Yes. FDA summarized six randomized, double-blind, placebo-controlled studies using oral or intravenous AOD-9604.⁵ They ranged from small, short studies to larger 12-week and 24-week trials in adults with obesity.⁸ Several key results were reported only in summaries rather than complete journal articles.⁵

Did the early studies report any signal?

Some did. Small studies reported increases in non-esterified fatty acids or modest numerical weight changes.² Those observations did not produce statistically significant weight differences from placebo in the four-week studies.⁹ The one-week numerical comparison also came with too little detail for a broad conclusion.¹⁰

What did the largest trial find?

OPTIONS randomized 502 adults with obesity to three oral AOD-9604 groups or placebo, alongside supervised diet and exercise.⁸ It found no statistically significant weight difference at the 12-week primary endpoint or the 24-week secondary endpoint.³ The developer then stopped the obesity program.³

Do the studies establish long-term safety?

No firm long-term conclusion follows from these summaries. Human exposure in the reviewed studies lasted no more than 24 weeks, and FDA noted missing event and laboratory detail.¹¹ Serious events were reported, but the available information did not establish whether several were caused by AOD-9604.¹²

Can oral trial findings answer questions about other routes?

Not on their own. FDA found the human safety information insufficient for subcutaneous or transdermal assessment.¹³ The agency also flagged possible immune-response, impurity, and characterization concerns for some compounded products and routes.⁴ Route and formulation therefore remain part of the evidence question.¹³

Sources

Footnotes

1. Detection and in vitro metabolism of AOD9604.. Canonical PubMed record for an analytical and in vitro metabolism study that defines the tested peptide. Chemical identity does not establish a human clinical outcome or show that similarly named fragments are interchangeable. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

2. FDA Briefing Document for AOD-9604 Related Bulk Drug Substances. Double-blind, dose-escalation study using single intravenous doses and placebo. The sample was small, the study was short, and FDA noted limited numerical and methodological detail. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

3. FDA Briefing Document for AOD-9604 Related Bulk Drug Substances. FDA review of the Phase IIb trial results and the developer's public announcement. The negative result applies to the tested oral doses, population, comparison, co-intervention, and follow-up period. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

4. FDA Briefing Document for AOD-9604 Related Bulk Drug Substances; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA effectiveness conclusion and current FDA compounding safety information. The conclusion concerns the evidence and compounded-product issues FDA reviewed; it is not a Philippine regulatory or availability statement. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

5. FDA Briefing Document for AOD-9604 Related Bulk Drug Substances. FDA synthesis of a sponsor-linked safety publication and other public materials from the clinical-development program. Several studies were available only through short summaries rather than full reports with complete methods and results. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹

6. Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.. Animal experiment in obese Zucker rats, not a human trial. The finding belongs to a rat model and cannot establish a human weight outcome. ↩ ↩²

7. FDA Briefing Document for AOD-9604 Related Bulk Drug Substances. METAOD005, available to FDA mainly as a scientific-meeting abstract rather than a complete publication. FDA noted minimal methodological detail, incomplete group reporting, and no located full publication of methods and results. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹²

8. FDA Briefing Document for AOD-9604 Related Bulk Drug Substances. Randomized, double-blind, placebo-controlled Phase IIb development study also identified as METAOD006. Publicly available efficacy information came from company filings and summaries rather than a full medical-journal report. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸

9. FDA Briefing Document for AOD-9604 Related Bulk Drug Substances. Small oral dose study summarized in FDA's briefing document. A short-term biomarker change is not the same endpoint as a demonstrated between-group weight outcome. ↩ ↩² ↩³ ↩⁴

10. FDA Briefing Document for AOD-9604 Related Bulk Drug Substances. Double-blind dose-escalation study summarized from limited public information. The numerical difference was not presented as a statistically significant result and cannot support a general efficacy conclusion. ↩ ↩² ↩³ ↩⁴

11. FDA Briefing Document for AOD-9604 Related Bulk Drug Substances. FDA summary of sponsor-funded human studies that monitored clinical and laboratory safety measures. FDA noted incomplete event breakdowns, missing laboratory values, and study durations of no more than 24 weeks. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷

12. FDA Briefing Document for AOD-9604 Related Bulk Drug Substances; Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. FDA review and current FDA compounding-risk information, including events reported in oral and intravenous studies. A reported event does not by itself establish causation, and the record was too limited for firm attribution. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

13. FDA Briefing Document for AOD-9604 Related Bulk Drug Substances. FDA review of the proposed compounded routes and the available human safety literature. This statement is limited to the scope and date of FDA's review. ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷